Genenta Science disclosed that the latest data cut from its TEM‑GBM Phase 1/2a study, conducted in newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT promoter, was completed on November 21 2025 and the results were released on November 24 2025. 25 patients had been treated, and the updated survival metrics show an 18‑month survival rate of 44 %, a two‑year survival rate of 29 %, and a median overall survival of 17 months—figures that match the previous November 15 cut and remain well above the historical two‑year survival benchmark of roughly 14 % for this patient population.
The survival outcomes represent a meaningful improvement over the historical median overall survival of 13‑15 months for unmethylated MGMT glioblastoma patients, underscoring the potential clinical benefit of Temferon. The 18‑month survival increase from 38 % in the earlier cut to 44 % suggests that the platform’s mechanism of action is translating into durable disease control, a key milestone for a first‑in‑class immuno‑oncology candidate.
Genenta’s preliminary immune data reinforce the platform’s design: bone‑marrow‑derived myeloid cells appear to deliver therapeutic payloads to the tumor microenvironment, reprogramming it and eliciting T‑cell responses. These observations support the hypothesis that Temferon can modulate the immune milieu in a way that may enhance the efficacy of future combination therapies, a strategy the company plans to pursue in later‑stage studies.
Financially, Genenta reported holding approximately $30 million in cash and short‑term investments as of November 1 2025, following a registered direct offering on October 27. While the company has no revenue and a negative earnings‑per‑share figure, the cash reserve provides a runway for the planned expansion of the TEM‑GBM program and the initiation of additional indication studies, such as metastatic renal cell carcinoma.
The data update triggered a 12.5 % pre‑market rise in Genenta’s stock on November 24, driven primarily by the favorable survival metrics and the confirmation of the platform’s immune‑modulating activity. Analysts highlighted the 18‑month survival improvement and the 44 % rate as key factors that bolstered investor confidence in the company’s clinical trajectory.
Genenta will continue to evaluate Temferon in larger, controlled trials and will explore combination strategies that leverage the observed immune reprogramming. The company’s next milestones include a Phase 2b expansion and the submission of a new clinical trial protocol to the FDA, positioning Temferon for potential regulatory approval in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.